DBL Pharmaceuticals, a subsidiary of DBL Group, is all set to buy the cream and ointment manufacturing line of GlaxoSmithKline Bangladesh as part of a plan to reintroduce the products of the British pharma giant.

Some of GSK’s widely consumed brands like Betnovate, Dermovate and Neobacrin are no longer available in Bangladesh since the end of 2018 when the multinational firm shut its drug manufacturing operations in the country.

DBL will bring alternatives of the discontinued GSK dermatological products to the market using the same technology, according to a statement of DBL Group.

GSK and DBL have informed the Directorate General of Drug Administration about the signing of a deal in this regard between the two entities on December 22.

DBL is establishing a Tk 700 crore pharmaceutical manufacturing plant following the standards of the US Food and Drug Administration at Kashimpur in Gazipur, which is expected to be fully operational by late 2020.